RYTM·76243J105·US·equity·Healthcare - Biotechnology-13D/G
RYTM (RHYTHM PHARMACEUTICALS INC) is held by 151 institutional investors as of Q1 2026. Largest holders: RA CAPITAL MANAGEMENT, L.P. ($579.8M), BlackRock, Inc. ($542.4M), BAKER BROS. ADVISORS LP ($487.4M). Net institutional sentiment: Mixed.
See how RYTM's score breaks down across 4 SEC sources
Data sourced from four SEC data sources: 13F, Form 4, 13D/13G, and STOCK Act. Not financial advice. Full disclaimer